CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 470 enrolled
Drug / intervention
Combivent CFC-MDI +2 moredrug
Likely dose
Combivent Respimat 20/100 mcgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01019694
NCT01019694Phase 3Completed
CompareCT.gov

Patient Acceptability of Ipratropium Bromide/Albuteroll Delivered by the Respimat® Inhaler in Adults With Chronic Obstructive Pulmonary Disease

Boehringer Ingelheim·interventional·Posted Nov 25, 2009·Updated Oct 23, 2014

In Brief

A Phase 3 clinical trial evaluating Combivent CFC-MDI, Combivent Respimat 20/100 mcg, and 1 other intervention for Pulmonary Disease, Chronic Obstructive. Completed, enrolled 470 participants across 55 sites.

Detailed Summary

The primary objective of this study is to evaluate long-term safety and patient acceptability of COMBIVENT RESPIMAT Inhalation Spray as compared to the COMBIVENT Inhalation Aerosol Chlorofluorocarbon-Metered Dose Inhaler (CFC-MDI) and the free combination of ATROVENT Hydrofluoroalkane (HFA) and albuterol Hydrofluoroalkane (HFA) inhalation aerosols.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPulmonary Disease, Chronic Obstructive
CountriesUnited States
Collaborators--

Timeline

Phase 3CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedNov 25, 2009
Enrollment StartNov 1, 2009
Primary CompletionApr 1, 2011
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 16.6 years ago

Interventions

Combivent CFC-MDIdrug

36/206 mcg Four times a day (QID)

Combivent Respimat 20/100 mcgdrug

Open label randomized parallel

Atrovent HFA 42 mcg + Albuterol HFA 200 mcgdrug

Open label randomized parallel